Journal
DIAGNOSTICS
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics12020539
Keywords
checkpoint inhibitors; immune related adverse events; cholestasis; severe ductopenia; vanishing bile duct syndrome
Categories
Ask authors/readers for more resources
The combination therapy of TKIs and ICIs in advanced ccRCC can result in high-grade toxicities, including vanishing bile duct syndrome. Immunological studies suggest the potential role of T-cells in the pathogenesis of the disease.
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report a patient with advanced metastatic ccRCC, who developed grade 4 cholestasis during combined therapy with nivolumab and cabozantinib. After the exclusion of common disorders associated with cholestasis and a failure of corticosteroids (CS), a liver biopsy was performed that demonstrated severe ductopenia. Consequently, a diagnosis of vanishing bile duct syndrome related to TKI and ICI administration was made, resulting in CS discontinuation and ursodeoxycholic acid administration. After a 7-month follow-up, liver tests had returned to normal values. Immunological studies revealed that our patient had developed robust T-cells and macrophages infiltrates in his lung metastasis, as well as in skin and liver tissues at the onset of toxicities. At the same time, peripheral blood immunophenotyping revealed significant changes in T-cell subsets, suggesting their potential role in the pathophysiology of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available